Bio-Path Holdings (BPTH) Presents New BP1003 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to Bio-Path Holdings (BPTH) Presents New BP1003 Data
April 12, 2022 4:01 PM EDT
HOUSTON, April 12, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today presented a poster highlighting preclinical BP1003 data at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
The poster, titled Targeting STAT3 with novel liposome-incorporated antisense oligonucleotide technology enhances the efficacy of paclitaxel (taxol) or 5-fluorouracil (5-FU) in breast and ovarian cancer cells, was presented by Dr. Maria Gagliardi, Research Scientist at Bio-Path Holdings.
"We are particularly pleased to have... More
